Celcuity (NASDAQ:CELC) Hits New 52-Week High – Here’s Why
by Danessa Lincoln · The Markets DailyCelcuity, Inc. (NASDAQ:CELC – Get Free Report)’s share price hit a new 52-week high on Friday . The company traded as high as $109.60 and last traded at $111.1850, with a volume of 213427 shares changing hands. The stock had previously closed at $100.77.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on CELC shares. Jefferies Financial Group lifted their target price on shares of Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Wells Fargo & Company initiated coverage on Celcuity in a research note on Friday. They issued an “overweight” rating and a $126.00 price target on the stock. Needham & Company LLC set a $95.00 price objective on Celcuity in a research report on Monday, October 20th. Wolfe Research initiated coverage on Celcuity in a report on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 target price on the stock. Finally, Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research note on Sunday, October 26th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $105.25.
Check Out Our Latest Stock Report on Celcuity
Celcuity Trading Up 7.5%
The company has a market capitalization of $5.01 billion, a P/E ratio of -29.92 and a beta of 0.21. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The stock has a fifty day moving average of $79.00 and a 200 day moving average of $48.47.
Celcuity (NASDAQ:CELC – Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. As a group, equities research analysts anticipate that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.
Insider Buying and Selling at Celcuity
In related news, Director Richard E. Buller sold 3,900 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the sale, the director owned 7,260 shares in the company, valued at approximately $702,259.80. This trade represents a 34.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.77% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Ogorek Anthony Joseph NY ADV purchased a new stake in Celcuity during the 3rd quarter valued at approximately $27,000. US Bancorp DE lifted its holdings in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Celcuity by 211.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after acquiring an additional 3,766 shares in the last quarter. Finally, Avanza Fonder AB purchased a new position in Celcuity during the third quarter valued at $79,000. 63.33% of the stock is owned by hedge funds and other institutional investors.
Celcuity Company Profile
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Stories
- Five stocks we like better than Celcuity
- Breakout Stocks: What They Are and How to Identify Them
- Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?
- Are Penny Stocks a Good Fit for Your Portfolio?
- 2 Small-Cap Biotechs That Could Reward Patient Investors
- What is the MACD Indicator and How to Use it in Your Trading
- Santa Claus May Be Coming Early for Palantir Investors